Phase 2 N=117 Randomized Quadruple-blind Treatment

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Primary Open Angle Glaucoma · Ocular Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT00595101 ↗

Enrolled (actual)

117

Serious AEs

0.0%

Results posted

Aug 2020

Primary outcome: Primary: Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 — -5.12; -5.94; -5.02; -5.25 mmHg (milimeters of mercury)

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: PF-03187207 (Drug); Latanoprost 0.005% (Drug); PF-03187207 Vehicle (Drug); Latanoprost Vehicle (Drug)
Age: Adult, Older Adult · 20+ yrs
Sex: All
Sponsor: Bausch & Lomb Incorporated
Primary completion: Jun 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28	-5.12; -5.94; -5.02; -5.25	—
SECONDARY Change From Baseline in Mean Intraocular Pressure (IOP) at Specific Time Points on Day 14 and Day 28	-5.20; -5.87; -4.35; -5.53; -5.63; -6.11	—
SECONDARY Target IOP	9; 11; 13; 9; 4; 2	—

Summary

To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension

Eligibility Criteria

Inclusion Criteria

Man or woman at least 20 years of age
Diagnosis of primary open-angle glaucoma or ocular hypertension in one or both eyes.

Exclusion Criteria

Closed/barely open anterior chamber angle or a history of acute angle closure in either eye
Contraindications to latanoprost and nitric oxide treatment
Known latanoprost non-responders

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00595101). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.